Industry
Biotechnology
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Loading...
Open
4.70
Mkt cap
306M
Volume
722K
High
5.54
P/E Ratio
-2.98
52-wk high
10.25
Low
4.57
Div yield
N/A
52-wk low
2.70
Portfolio Pulse from
December 12, 2024 | 3:45 pm
Portfolio Pulse from
November 29, 2024 | 6:15 pm
Portfolio Pulse from
November 25, 2024 | 4:15 pm
Portfolio Pulse from
November 05, 2024 | 12:30 pm
Portfolio Pulse from Benzinga Newsdesk
October 10, 2024 | 11:19 am
Portfolio Pulse from Benzinga Newsdesk
September 24, 2024 | 11:29 am
Portfolio Pulse from Benzinga Newsdesk
September 03, 2024 | 12:44 pm
Portfolio Pulse from Avi Kapoor
August 19, 2024 | 5:37 pm
Portfolio Pulse from Avi Kapoor
August 19, 2024 | 2:25 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.